Oncology
1 drug is in development for B-cell Lymphoma.
- Companies
- 1
- Clinical trials
- 12
BioSniper AIPage evidence connected
Prepared research question
Which programs lead the B-cell Lymphoma pipeline—and what evidence could change the picture?
Run cited research
Traceable citations · Unknowns marked
Drug Pipeline by Phase
Phase 1(1)
| Drug | Company |
|---|---|
| CTX112 | CRISPR Therapeutics AG (CRSP) |
About this indication
B-cell Lymphoma context
Oncology·MeSH: Lymphoma, B-Cell (D016393)
Also known as: B-Cell Lymphomas
Prevalence
56.0 / 100K
Incidence
19.6 / 100K/yr
Frequently asked questions
How many drugs are in development for B-cell Lymphoma?
BioSniper tracks 1 drug in development for B-cell Lymphoma across 1 company.
How many clinical trials target B-cell Lymphoma?
There are 12 clinical trials targeting B-cell Lymphoma tracked by BioSniper.
What is the prevalence of B-cell Lymphoma?
The estimated prevalence of B-cell Lymphoma is approximately 56.0 per 100,000 population.